TY - BOOK ID - 8580999 TI - Chronic myeloid neoplasias and clonal overlap sydromes : epidemiology, pathophysiology and treatment options PY - 2010 SN - 3211798919 9786612983221 3211798927 1282983229 PB - Vienna : Springer, DB - UniCat KW - Myeloid leukemia --Epidemiology. KW - Myeloid leukemia --Pathophysiology. KW - Myeloid leukemia --Treatment. KW - Myeloproliferative disorders --Epidemiology. KW - Myeloproliferative disorders --Pathophysiology. KW - Myeloproliferative disorders --Treatment. KW - Myeloproliferative disorders KW - Myeloid leukemia KW - Bone Marrow Diseases KW - Leukemia KW - Leukemia, Myeloid KW - Myeloproliferative Disorders KW - Neoplasms by Histologic Type KW - Hematologic Diseases KW - Neoplasms KW - Hemic and Lymphatic Diseases KW - Diseases KW - Medicine KW - Oncology KW - Health & Biological Sciences KW - Epidemiology KW - Pathophysiology KW - Treatment KW - Bone marrow KW - Myeloproliferative disorders. KW - Myelodysplastic syndromes. KW - Diseases. KW - Dysmyelopoietic syndromes KW - Myeloproliferative syndrome KW - Dysplasia KW - Medicine. KW - Internal medicine. KW - Blood transfusion. KW - Oncology. KW - Medicine & Public Health. KW - Internal Medicine. KW - Blood Transfusion Medicine. KW - Syndromes KW - Preleukemia KW - Oncology  . KW - Blood transfusion KW - Blood transfusion therapy KW - Hemotherapy KW - Transfusion medicine KW - Transfusion of blood KW - Transfusion therapy KW - Transfusion therapy, Blood KW - Surgery KW - Blood banks KW - Blood groups KW - Hospitals KW - Transfusion-free surgery KW - Medicine, Internal KW - Tumors KW - Transfusion committees UR - https://www.unicat.be/uniCat?func=search&query=sysid:8580999 AB - Introduction The understanding of the genetic, epigenetic, immuno- well as for practicing hematologists or oncologists. logical and biological causes of myeloproliferative dis- Each chapter follows a similar architecture and leads orders has substantially improved in the last few years. through epidemiology, genetic and molecular causes, Together with refined tools in pathology, the successful hematological and clinical findings, prognostic factors establishment of mouse models mimicking at least some and current treatment approaches of the diseases. of the myeloproliferative disorders, and murine models Effort has been made to point out the evolving field of novel drugs in this arena but simultaneously diff- allowing to carefully dissect the role of mutations and gene dosage effects of, for example JAK2, this has led to entiate between standard and experimental treatment ever increasing numbers of modified classification approaches. schemes. It is therefore important for the heamtologist Together with the co-editors and all the authors of or oncologist to keep up with this rapid change in classi- the various chapters I hope that the readers of the book fication language, the upcoming of new entities or differ- will enjoy reading and benefit from the information entiation between, or subclassification of, rare diseases provided. ER -